赫赛汀治疗人类表皮生长因子受体-2阳性乳腺癌的疗效

Efficacy of Herceptin in the Treatment of Human Epidermal Growth Factor Receptor-2 Positive Breast Cancer

目的:分析赫赛汀治疗人类表皮生长因子受体-2(HER-2)阳性乳腺癌的临床疗效。方法:选择2013年1月—2016年1月在我院收治的78例HER-2阳性乳腺癌患者,按照随机数表的方法将78例患者分为两组,分别为对照组和观察组,每组各39例,对照组行常规化疗治疗,观察组在常规化疗方案的基础上添加赫赛汀治疗,所有患者均随访6个月,对比两组患者的治疗效果及患者的药物不良反应。结果:观察组的治疗有效率为82.1%,对照组的治疗有效率为61.5%,观察组的治疗有效率高于对照组,P<0.05;两组均未发生Ⅲ度以上的不良反应,不良反应主要以发热、皮疹、骨髓抑制和消化系统症状为主,经对症处理后均好转,观察组与对照组的各不良反应发生率无显著差异,P>0.05。结论:应用赫赛汀治疗HER-2阳性乳腺癌具有显著的治疗效果,且不增加患者的不良反应,值得在临床推广。

Objective:To evaluate the clinical efficacy of Herceptin in the treatment of HER-2positive breast cancer.Methods:Seventy-eight patients with HER-2positive breast cancer who were admitted to our hospital were divided into two groups according to the method of random number table:control group and observation group,with39cases in each group.All patients were followed up for6months.The therapeutic effect of the two groups was compared with that of the patients,and the adverse drug reactions were observed in the treatment group.Results:The effective rate was82.1%in the observation group and61.5%in the control group.The effective rate in the observation group was higher than that in the control group(P<0.05).No level III or above adverse reaction was found in the two groups.The main reactions were fever,rash,myelosuppression and digestive system symptoms.The symptoms was markedly improved,and the incidence of adverse reactions between the observation group and the control group showed no significant difference(P>0.05).Conclusion:Herceptin has a significant therapeutic effect on HER-2-positive breast cancer and does not increase the adverse effects of herceptin,thus it is worthy of clinical application.